the mechanism whereby adcc or its in vivo expression confers a survival advantage is unknown but we suggest that it derives from immunoreactivity against blood group a antigens produced inappropriately in the carcinomatous epithelium of the group o and b patients .
C0003272
adcc
C0003320
antigens